$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
What targets does cabozantinib contain and its mechanism of action?
2026-02-01 22:25:32
Check Details
Price list analysis of targeted drug lorlatinib/lorlatinib in 2025
2026-02-01 22:25:32
Check Details
Comparison of the efficacy of upadatinib generic drugs: analysis of differences with the original drug
2026-02-01 22:25:32
Check Details
Will Teclistamab-cqyv be covered by medical insurance in 2025?
2026-02-01 22:25:32
Check Details
QuANTUM-Wild trial explores outcomes associated with quizatinib in FLT3-negative AML
2026-02-01 22:25:32
Check Details
Elotuzumab/pomalidomide combination elicits responses in relapsed/refractory MM
2026-02-01 22:25:32
Check Details
Is lapatinib officially included in medical insurance? What is the reimbursement status?
2026-02-01 22:25:32
Check Details
What contraindications should you pay attention to when using filgotinib?
2026-02-01 22:25:32
Check Details
Latest market price per box of Trientine capsules
2026-02-01 22:25:32
Check Details
Monitoring of gene mutations during the treatment of chronic myelitis with bosutinib/bosutinib
2026-02-01 22:25:32
Check Details
What is the current status of Milizumab in the Chinese market?
2026-02-01 22:25:32
Check Details
Detailed introduction to the drug MEK inhibitor selumetinib
2026-02-01 22:25:32
Check Details
1
2
...
1648
1649
1650
1651
1652
1653
1654
...
10226
10227
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
2
Asciminib (SCEMBLIX): STAMP Inhibitor Dosing Guide and Nomenclature Clarification for CML
3
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights
4
Cabergoline Medication Guide: Contraindications, Treatment Costs, and Safety Monitoring Essentials
5
Pemigatinib vs. Anlotinib: Key Differences Between FGFR-Targeted Therapy and Multi-Target Anti-Angiogenic Treatment
6
Enasidenib (IDHIFA): A Comprehensive Guide to Targeted Therapy for IDH2-Mutated Acute Myeloid Leukemia
7
Midostaurin vs. Gilteritinib: Key Differences in FLT3-Targeted AML Therapy
8
Lapatinib: A Targeted Anticancer Agent — Not Merely Symptom Relief
9
Filgotinib: Mechanism of Action and Clinical Applications Explained
10
Lapatinib: Proper Administration Guide and Key Precautions
11
Capivasertib (Truqap) Complete Medication Guide: Indications, Dosing, Safety, and Precautions
12
Cemiplimab Storage and Handling Guide